AMCP was pleased that the bill, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974), bipartisan legislation designed to increase patient access to safe and affordable generic and biosimilar medicines and marketplace competition, continued to garner bipartisan support when it was voted out of the Judiciary Committee.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide comments in response to the Department of Health and Human Services’ (HHS’s) request for information on the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs [RIN 0991-ZA49] (Blueprint).
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to “Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities—Questions and Answers [FDA-2016-D-1307]” as published in the Federal Register on June 13, 2018.
The Alliance wants to ensure an FDA that is sized and modernized to meet its mandate in the 21st century. The FDA oversees products that represent 20% of consumer spending in the US and affect every American multiple times each day. Its responsibilities are global in scope and form the backbone of the world’s economy.
AMCP CEO Blog: Summer is in full swing! It’s time to enjoy a good barbecue, go to the beach, soak up the sun, and dine with friends at your favorite sidewalk cafe. At AMCP, it’s also a time to engage with the Academy’s volunteer leadership, as well as a diverse array of health care stakeholders...who said pharmacists ever slow down when the weather gets hot?
Press Release: As the Academy of Managed Care Pharmacy (AMCP) Foundation marks its 28th anniversary today, the organization celebrates another successful philanthropic effort from this spring.
Press Release: The Academy of Managed Care Pharmacy (AMCP) commends the U.S. Food and Drug Administration (FDA) for issuing final guidance that clarifies how manufacturers can communicate truthful and non-misleading information with payers across a product’s lifecycle.
On behalf of the Academy of Managed Care Pharmacy (AMCP), I wanted to take this opportunity to express our strong support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974), bipartisan legislation to increase competition and patient access to safe and affordable generic and biosimilar medicines.
AMCP CEO Blog: The White House made news last month with its blueprint to lower drug prices. But it's also important to note that biosimilars will play a crucial role in fostering competition and lowering costs.